PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pyxis Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.76+0.08 (+4.76%)
Close on Oct 19, 2026
- Market cap
- $112.63M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
82.8%
Operating margin
-609.2%
Net margin
-574.5%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -14.2% | – | – | – | |
| Gross profit | -26.8% | – | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 138.5% | -91.4% | |
| Return on assets | – | – | -64.0% | |
| Current ratio | – | 2.20 | 3.41 | |
| Capex to revenue | – | – | 0.1% | |
| Diluted shares | – | 1M | 62M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Pyxis Oncology generated $316.54M from operations and spent $13.91M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$316.54M
Used
$13.91M
Capital expenditure$13.91M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-574.5%
×Asset turnover0.11×
×Equity multiplier1.43×
=Return on equity, FY2025-91.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -574.5% | 0.11× | 1.43× | -91.4% |
| FY2024 | -478.9% | 0.10× | 1.34× | -62.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$79.62M
- Cash generatingOperating cash flow above zero-$63.50M
- Return on assets improvedROA up on the prior year-44.5% → -50.7%
- Earnings backed by cashOperating cash flow above net income-$63.50M vs -$79.62M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.49 → 3.41
- No dilutionShare count did not rise58M → 62M
- Gross margin improvedGross margin up on the prior year97.06% → 82.77%
- More efficientAsset turnover rose0.09 → 0.09